Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Mavacamten via NG Tube
NCT06211179Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration up to 37 days, Area under the concentration-time curve from time 0 to last quantifiable time point up to 37 days and 2 more. Started Jan 2024; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06211179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211179.